Dr Januzzi raises several interesting points regarding galectin-3 levels after acute myocardial infarction. We found that galectin-3 increased modestly but significantly (by ≈12%) between baseline (≈day 2) and 24 weeks. 1 Serial measurement of galectin-3 in healthy volunteers suggests a reference change value of the order of 61% for galectin-3. 2 A recent analysis of serial galectin-3 levels in 2 chronic heart failure trials suggests, however, that a rise in galectin-3 of only ≥15% for 3 to 6 months confers an increased risk of adverse outcomes. 3 It is perhaps possible that smaller fluctuations of galectin-3 in the setting of profibrotic disease states (such as acute myocardial infarction and chronic heart failure) are pathophysiologically relevant. It is also feasible that plasma galectin-3 concentrations may not correlate directly with tissue levels; myocardial galectin-3 content may be significantly in excess of circulating galectin-3.
We found that galectin-3 concentrations increased significantly (by ≈14%) in patients treated with eplerenone in our study. Further analysis, as requested by Dr Januzzi, revealed no effect of eplerenone on remodeling, whether baseline galectin-3 levels were low (<median) or high (≥median). We agree that the rise in galectin-3 in eplerenonetreated patients is at odds with conventional wisdom, which would predict a decrease in galectin-3 with the use of a mineralocorticoid receptor antagonist. Although this may simply relate to our trial design-it was powered for cardiac MRI end points-a rise in galectin-3 in those receiving mineralocorticoid receptor antagonists was also seen in patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Whether the antifibrotic effects of mineralocorticoid receptor antagonists trigger feedback upregulation of galectin-3 (and if so, by what mechanism), whether galectin-3 rises in response to mineralocorticoid receptor antagonist-induced renal dysfunction, or whether there is any relationship at all between galectin-3 and the aldosterone pathway remains unclear and is the focus of ongoing study. Galectin-3 is undoubtedly a risk marker in patients with heart failure; whether it represents a modifiable therapeutic target to improve outcome and reduce remodeling in both acute myocardial infarction and chronic heart failure remains unknown.
